Results 101 to 110 of about 22,035 (254)

Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation [PDF]

, 2017
Introduction Monotherapy with protease-inhibitors (MPI) may be an alternative to cART for HIV treatment. We assessed the impact of this strategy on immune activation, bacterial translocation and inflammation.
García Alcaide, Felipe, Gatell, José M., González Cordón, Ana, Guardo, Alberto C., Leal, Lorna, León García, Agathe, Lucero, Constanza, Martínez Rebollar, María, Martínez Yoldi, Miguel Julián, Plana Prades, Montserrat, Torres, Berta, Vila Estapé, Jordi, Álvarez Martínez, Míriam   +12 more
core   +1 more source

Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.

Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND Darunavir/ritonavir is better tolerated than lopinavir/ritonavir and has a higher genetic barrier to resistance. Co-administration with rifampicin has been contraindicated as a significant reduction in darunavir exposure is expected. This is a
I. Ebrahim, G. Maartens, L. Wiesner, C. Orrell, W. Smythe, H. McIlleron   +5 more
semanticscholar   +1 more source

Elevated Serum Lipopolysaccharides and Intrinsic Factor Autoantibodies Correlate With Macrocytic Anemia Among People With HIV

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Introduction Human immunodeficiency virus (HIV) infection is associated with various comorbidities, including macrocytic anemia, though the role of the infection is unclear. HIV has been implicated in microbial translocation and altered immune responses.
Daniel Amakye, Samuel Hammond, Osbourne Quaye, Upal Roy, Peter Puplampu, Vincent Ganu, Emmanuel Ayitey Tagoe   +6 more
wiley   +1 more source

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

Therapeutics and Clinical Risk Management, 2009
Michael Neely, Andrea KovacsUniversity of Southern California Keck School of Medicine, Department of Pediatrics, Division of infectious Diseases, Los Angeles, CA, USAAbstract: Darunavir is currently the most recently approved HIV-1 protease inhibitor. It
Michael Neely, Andrea Kovacs
doaj  

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

HIV Research & Clinical Practice, 2020
Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.
Valentina Di Cristo, Fulvio Adorni, Renato Maserati, Marco Annovazzi Lodi, Giuseppe Bruno, Paolo Maggi, Anna Volpe, Paola Vitiello, Clara Abeli, Stefano Bonora, Micol Ferrara, Maria Vittoria Cossu, Maria Letizia Oreni, Elisa Colella, Stefano Rusconi   +14 more
doaj   +1 more source

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir [PDF]

, 2016
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV).
Chadwick, D, Hamzah, L, Jones, R, Jose, S, Nelson, M, Phillips, A, Post, FA, Sabin, CA, Trevelion, R, Williams, DI   +9 more
core   +2 more sources

Long‐Term Control of Human Papillomavirus‐Related Focal Epithelial Hyperplasia in an Human Immunodeficiency Virus‐Positive Patient Using Methylene Blue‐Mediated Photodynamic Therapy. A Case Report

Lasers in Surgery and Medicine, Volume 58, Issue 2, Page 70-73, February 2026.
ABSTRACT Background Human papillomavirus (HPV) infections are a major cause of oral lesions, and in individuals living with HIV, lesions such as focal epithelial hyperplasia (FEH) may persist or exhibit atypical features, potentially progressing to more severe conditions if untreated.
Juliana Cristina Oliverio de Araújo, Hermano Camelo Paiva, Paula Margarida Meyer Faara, Og Fray Junior, Martha Simões Ribeiro   +4 more
wiley   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Post-Marketing Pharmacovigilance Study of Darunavir in the United Kingdom: An Analysis of Adverse Drug Reactions Reported to the MHRA

Pharmacoepidemiology
Background/Objectives: Human immunodeficiency virus (HIV) continues to be a global public health concern. Several antiretroviral drugs have been approved for the treatment, post-exposure, and pre-exposure prophylaxis of HIV. Darunavir (DRV) is a protease
Pono Pono, Vicky Cheng, Victoria Skerrett, Alan M. Jones   +3 more
doaj   +1 more source